AN2 Therapeutics, Inc.
ANTX Nasdaq
SEC CIK 1880438
Follow AN2 Therapeutics
Weekly email: filings, results
Net income
−$8M
+14.9% vs same quarter last year
EPS, diluted
−$0.17
+45.2% vs same quarter last year
Operating cash flow
−$6.1M
+4.3% vs same quarter last year
Operating income
−$8.7M
+13.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$35.2M |
| FY24 | −$51.3M |
| FY23 | −$64.7M |
| FY22 | −$41M |
| FY21 | −$21.5M |
| FY20 | - |